TRITACE 10 TABLET 10 mg
देश: सिंगापुर
भाषा: अंग्रेज़ी
स्रोत: HSA (Health Sciences Authority)
सूचना पत्रक
(PIL)
03-10-2014
इस उत्पाद के लिए कुछ दस्तावेज़ वर्तमान में उपलब्ध नहीं हैं, आप हमारी ग्राहक सेवा को अनुरोध भेज सकते हैं और जैसे ही हम उन्हें प्राप्त करने में सक्षम होंगे, हम आपको सूचित करेंगे।
अनुरोध भेजा।
अनुरोध भेजा।
सक्रिय संघटक:
RAMIPRIL
थमां उपलब्ध:
SANOFI-AVENTIS SINGAPORE PTE. LTD.
ए.टी.सी कोड:
C09AA05
डोज़:
10 mg
फार्मास्यूटिकल फॉर्म:
TABLET
प्रशासन का मार्ग:
ORAL
प्रिस्क्रिप्शन प्रकार:
Prescription Only
द्वारा बनाया गया:
SANOFI-AVENTIS S.P.A.
प्राधिकरण की तारीख:
2001-12-28
सूचना पत्रक
This package insert is continually updated: please read carefully
before using a new pack!
TRITACE
®
1.25 TABLETS
TRITACE
®
2.5 TABLETS
TRITACE
®
5 TABLETS
TRITACE
®
10 TABLETS
_Ramipril _
_ _
[SANOFI LOGO]
COMPOSITION
Each tablet Tritace
®
1.25 contains, as active ingredient, 1.25 mg ramipril.
Each tablet Tritace
®
2.5 contains, as active ingredient, 2.5 mg ramipril.
Each tablet Tritace
®
5 contains, as active ingredient, 5 mg ramipril.
Each tablet Tritace
®
10 contains, as active ingredient, 10 mg ramipril.
Excipients: Methylhydroxypropylcellulose, pregelatinized maize
starch,
microcrystalline cellulose, sodium stearyl fumarate, yellow ferric
oxide
(Tritace 2.5 only), red ferric oxide (Tritace 5 only).
Not all presentation is available in all countries.
PROPERTIES
Ramiprilat, the active metabolite of ramipril, is a potent and
long-acting angiotensin converting enzyme (ACE) inhibitor.
Administration of Tritace results in a vasodilatation and,
especially in hypertensive patients, in a reduction of blood
pressure.
The blood-pressure-lowering effect of a single dose occurs within 1
– 2 hours after intake, reaching its peak within 3 - 6 hours, and
usually lasts 24 hours.
Tritace is also effective in the treatment of congestive heart
failure.
Further, in patients demonstrating clinical signs of congestive heart
failure after an acute myocardial infarction, Tritace has been
shown to decrease the mortality risk (including the risks of sudden
death, of progression to severe/resistant heart failure and of
failure-related hospitalisation).
Tritace, when administered on a preventive basis,
significantly reduces the incidence of myocardial infarction, stroke
or
cardiovascular deaths in patients with an
increased cardiovascular risk attributable to vascular diseases
(such as manifest coronary
heart disease, or a history of stroke or of peripheral vascular
disease) or to diabetes mellitus with at l
पूरा दस्तावेज़ पढ़ें
